Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

Show simple item record

dc.contributor.author Lara, PN en
dc.contributor.author Douillard, JY en
dc.contributor.author Nakagawa, K en
dc.contributor.author von Pawel, J en
dc.contributor.author McKeage, Mark en
dc.contributor.author Albert, I en
dc.contributor.author Losonczy, G en
dc.contributor.author Reck, M en
dc.contributor.author Heo, DS en
dc.contributor.author Fan, X en
dc.contributor.author Fandi, A en
dc.contributor.author Scagliotti, G en
dc.coverage.spatial United States en
dc.date.accessioned 2012-03-06T19:20:38Z en
dc.date.issued 2011 en
dc.identifier.citation Journal of Clinical Oncology 29(22):2965-2971 2011 en
dc.identifier.issn 0732-183X en
dc.identifier.uri http://hdl.handle.net/2292/13078 en
dc.description.abstract This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone. en
dc.language eng en
dc.publisher American Society of Clinical Oncology en
dc.relation.ispartofseries Journal of Clinical Oncology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0732-183X/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Adult en
dc.subject Aged en
dc.subject Angiogenesis Inhibitors en
dc.subject Antineoplastic Combined Chemotherapy Protocols en
dc.subject Carboplatin en
dc.subject Carcinoma, Non-Small-Cell Lung en
dc.subject Disease-Free Survival en
dc.subject Double-Blind Method en
dc.subject Drug Administration Schedule en
dc.subject Female en
dc.subject Humans en
dc.subject Kaplan-Meier Estimate en
dc.subject Lung Neoplasms en
dc.subject Male en
dc.subject Middle Aged en
dc.subject Neoplasm Staging en
dc.subject Odds Ratio en
dc.subject Paclitaxel en
dc.subject Quality of Life en
dc.subject Questionnaires en
dc.subject Treatment Failure en
dc.subject Xanthones en
dc.title Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. en
dc.type Journal Article en
dc.identifier.doi 10.1200/JCO.2011.35.0660 en
pubs.issue 22 en
pubs.begin-page 2965 en
pubs.volume 29 en
dc.rights.holder Copyright: American Society of Clinical Oncology en
dc.identifier.pmid 21709202 en
pubs.end-page 2971 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 213944 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Pharmacology en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
dc.identifier.eissn 1527-7755 en
dc.identifier.pii JCO.2011.35.0660 en
pubs.record-created-at-source-date 2012-02-15 en
pubs.dimensions-id 21709202 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace